Skip to main content
OVIDOvid Therapeutics Inc.Sell5.7·$2.20
SellModerate Confidence
Investment thesis

Ovid Therapeutics is a cash-burning, near-pre-revenue biotech with large analyst-implied upside and a pullback within a rising trend, but quality is below the floor and leverage is flagged as high.

Thesis pillars

  • Large Analyst Upside→Stable
  • Severe Cash Burn→Stable
  • Pullback In Rising Trend↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Oct 24, 2026, based on the 10-K filed Mar 18, 2026

Full reasoning →

Open full analysis

Ovid Therapeutics Inc. (OVID) Stock Analysis

Inst Constrain edge

SellVALUE-TRAP 2/5QualityModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $2.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 8.60; Below-average business quality.

Ovid Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for brain disorders driven by neuronal hyperexcitability, including OV329, a GABA-aminotransferase inhibitor in Phase 1 development for drug-resistant seizures, and a KCC2... Read more

$2.20+143.2% A.UpsideScore 5.7/10#63 of 240 Biotechnology
QualityF-score5 / 9FCF yield-8.37%
Stop $2.05Analyst target $5.35(−13% haircut)A.R:R 9.6:1
Analyst consensus$6.15+179.5%10 analysts with price targets
$5.35Analyst target
$2.20price
$6.15mean
$9

Sell if holding. Engine safety override at $2.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 8.60; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 115d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.

10-K grounded · weekly refresh

About Ovid Therapeutics Inc.

About Ovid Therapeutics Inc.

Ovid Therapeutics has no approved drugs and no product revenue, funding its neuroscience pipeline with $90.4 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which the company expects will cover operations for at least the next 12 months. Its lead clinical program, OV329, a GABA-aminotransferase inhibitor for drug-resistant seizures, has completed Phase 1 dosing with regulatory discussions underway for Phase 2, while OV4071, the lead candidate from Ovid's KCC2 direct-activator library, is expected to begin a Phase 1 trial in the second quarter of 2026 for psychosis associated with Parkinson's disease and Lewy body dementia.

Since it has no marketed products, Ovid generates no revenue and instead builds its pipeline primarily through in-licensing and business development rather than internal discovery; the company has assembled five clinical-stage programs targeting epilepsy, developmental and epileptic encephalopathies, and psychosis tied to Parkinson's disease, Lewy body dementia, and schizophrenia. OV329 targets an already-validated GABA-AT mechanism and is designed to improve on vigabatrin, an older approved anti-seizure drug limited by irreversible vision-loss side effects, while the KCC2 library, built from more than 100 in-house molecules, addresses a target the company says is uniquely expressed in the central nervous system. Ovid reported a $17.4 million net loss for 2025 against a $321.7 million accumulated deficit, reflecting years of preclinical and clinical spending with no offsetting product sales.

Show full overview

Ovid's disclosed cash runway of approximately 12 months from its financial statement issuance date is shorter than the multi-year runway many clinical-stage peers report, meaning the company may need to raise additional capital, through equity, debt, or a licensing partnership, before either of its lead programs, OV329 or OV4071, reaches a late-stage readout. The 10-K also flags reliance on third-party manufacturers for all clinical and prospective commercial drug supply, since Ovid has no in-house manufacturing capability of its own.

See also: Healthcare · Biotechnology

From Ovid Therapeutics Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 18, 2026

Recent Developments — Ovid Therapeutics Inc.

Latest item Nov 18, 2026 · Generated 2026-11-22T11:47:07Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Mar 17, 2027115d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.4 < 4.0)
Value-trap signals (2/5): High leverage (D/E 1.9), Negative free cash flow

Key Metrics

P/E (TTM)—
P/E (Fwd)-5.4
Mkt Cap$415M
EV/EBITDA-4.3
Profit Mgn0.0%
ROE-35.4%
Rev Growth—
Beta0.24
DividendNone
Analysts with ratings19

Quality Signals

Piotroski F5/9MoatNarrow

Options Flow

P/C8.60bearish
IV225%elevated

Material Events(8-K, last 90d)

  • 2026-06-03Item 5.02LOW
    Ovid's Board approved an increase in board size and the appointment of Dr. Anna Greka, a Harvard Medical School professor, as a Class III director effective June 15, 2026, with a term expiring at the 2029 annual meeting. Dr. Greka was also named to the Compensation and Science and Technology Committees; no departure or replacement was involved.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
2.2
Macd
3.0
Volume
4.1
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+5.0%/30d) — pullback in uptrend, not confirmed weakness

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Net Margin
0.0
Fcf Quality
0.0
Current Ratio
5.0
Piotroski F
5.6
Moat
6.2
Gross Margin
10.0
Cash-burning: FCF -2393% of revenue
GatesMomentum 3.0<4.5Executive change: officer departure/appointmentA.R:R 9.6 ≥ 1.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 115d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
44 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $2.10Resistance $3.09

Price Targets

$2
$5
A.Upside+143.2%
A.R:R9.6:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (3.4 < 4.0)
! Value-trap signals (2/5): High leverage (D/E 1.9), Negative free cash flow
! momentum at 3.0 (below the engine's 4.5 threshold)

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-03-17 (115d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OVID stock a buy right now?

Sell if holding. Engine safety override at $2.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 8.60; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $2.05. Score 5.7/10, moderate confidence.

What is the OVID stock price target?

Analyst target: $5.35 (+143.2% upside). Prior stop was $2.05. Stop-loss: $2.05.

What are the risks of investing in OVID?

Quality below floor (3.4 < 4.0); Value-trap signals (2/5): High leverage (D/E 1.9), Negative free cash flow.

Is OVID overvalued or undervalued?

Ovid Therapeutics Inc. trades at a P/E of N/A (forward -5.4). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about OVID?

19 analysts rate OVID, with a consensus score of 4.4/5. 10 analysts publish price targets averaging $6.

What does Ovid Therapeutics Inc. do?Ovid Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for brain disorders...

Ovid Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for brain disorders driven by neuronal hyperexcitability, including OV329, a GABA-aminotransferase inhibitor in Phase 1 development for drug-resistant seizures, and a KCC2 direct-activator platform, led by OV4071, targeting psychosis associated with Parkinson's disease and Lewy body dementia. The company has no products approved for commercial sale and has never generated product revenue, reporting a $17.4 million net loss for 2025 against an accumulated deficit of $321.7 million, with $90.4 mil

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I) · MGTX (MeiraGTx Holdings plc)
Home › Stocks › OVID

Latest news

Latest News

Fiscal.ai4d ago
Fiscal.ai5d ago
Fiscal.ai12d ago
Benzinga12d ago
Fiscal.ai13d ago
Benzinga13d ago
Fiscal.ai17d agoEarnings
Fiscal.ai17d ago
Benzinga38d ago
Benzinga44d ago
Benzinga47d ago
Benzinga54d ago
Benzinga101d ago
Benzinga111d ago
Benzinga137d agoLeadership Change
Benzinga138d ago